These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 37685642)

  • 1. Long-Acting Buprenorphine Formulations as a New Strategy for the Treatment of Opioid Use Disorder.
    Maremmani I; Dematteis M; Gorzelanczyk EJ; Mugelli A; Walcher S; Torrens M
    J Clin Med; 2023 Aug; 12(17):. PubMed ID: 37685642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medication Treatment of Opioid Use Disorder.
    Bell J; Strang J
    Biol Psychiatry; 2020 Jan; 87(1):82-88. PubMed ID: 31420089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rationale, design and methods of VA-BRAVE: a randomized comparative effectiveness trial of two formulations of buprenorphine for treatment of opioid use disorder in veterans.
    Petrakis I; Springer SA; Davis C; Ralevski E; Gu L; Lew R; Hermos J; Nuite M; Gordon AJ; Kosten TR; Nunes EV; Rosenheck R; Saxon AJ; Swift R; Goldberg A; Ringer R; Ferguson R
    Addict Sci Clin Pract; 2022 Jan; 17(1):6. PubMed ID: 35101115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of Treatments for Opioid Use Disorder.
    Fairley M; Humphreys K; Joyce VR; Bounthavong M; Trafton J; Combs A; Oliva EM; Goldhaber-Fiebert JD; Asch SM; Brandeau ML; Owens DK
    JAMA Psychiatry; 2021 Jul; 78(7):767-777. PubMed ID: 33787832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Initiating opioid agonist treatment for opioid use disorder nationally in the Veterans Health Administration: Who gets what?
    Manhapra A; Stefanovics E; Rosenheck R
    Subst Abus; 2020; 41(1):110-120. PubMed ID: 31403914
    [No Abstract]   [Full Text] [Related]  

  • 6. Recommendations for buprenorphine and methadone therapy in opioid use disorder: a European consensus.
    Dematteis M; Auriacombe M; D'Agnone O; Somaini L; Szerman N; Littlewood R; Alam F; Alho H; Benyamina A; Bobes J; Daulouede JP; Leonardi C; Maremmani I; Torrens M; Walcher S; Soyka M
    Expert Opin Pharmacother; 2017 Dec; 18(18):1987-1999. PubMed ID: 29183228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Opioid-related treatment, interventions, and outcomes among incarcerated persons: A systematic review.
    Malta M; Varatharajan T; Russell C; Pang M; Bonato S; Fischer B
    PLoS Med; 2019 Dec; 16(12):e1003002. PubMed ID: 31891578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medications for management of opioid use disorder.
    Koehl JL; Zimmerman DE; Bridgeman PJ
    Am J Health Syst Pharm; 2019 Jul; 76(15):1097-1103. PubMed ID: 31361869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medications for Maintenance Treatment of Opioid Use Disorder in Adolescents: A Narrative Review and Assessment of Clinical Benefits and Potential Risks.
    Camenga DR; Colon-Rivera HA; Muvvala SB
    J Stud Alcohol Drugs; 2019 Jul; 80(4):393-402. PubMed ID: 31495374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of opioid withdrawal and initiation of medications for opioid use disorder in the hospital setting.
    Carswell N; Angermaier G; Castaneda C; Delgado F
    Hosp Pract (1995); 2022 Oct; 50(4):251-258. PubMed ID: 35837678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prolonged-release opioid agonist therapy: qualitative study exploring patients' views of 1-week, 1-month, and 6-month buprenorphine formulations.
    Neale J; Tompkins CNE; Strang J
    Harm Reduct J; 2019 Apr; 16(1):25. PubMed ID: 30943990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. METHADONE INITIATION IN THE EMERGENCY DEPARTMENT FOR OPIOID USE DISORDER: A CASE SERIES.
    Huo S; Heil J; Salzman MS; Carroll G; Haroz R
    J Emerg Med; 2023 Mar; 64(3):391-396. PubMed ID: 37019500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trends in and Characteristics of Buprenorphine Misuse Among Adults in the US.
    Han B; Jones CM; Einstein EB; Compton WM
    JAMA Netw Open; 2021 Oct; 4(10):e2129409. PubMed ID: 34652446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current and future options for opioid use disorder: a survey assessing real-world opinion of service users on novel therapies including depot formulations of buprenorphine.
    Gilman M; Li L; Hudson K; Lumley T; Myers G; Corte C; Littlewood R
    Patient Prefer Adherence; 2018; 12():2123-2129. PubMed ID: 30349206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prior National Drug Abuse Treatment Clinical Trials Network (CTN) opioid use disorder trials as background and rationale for NIDA CTN-0100 "optimizing retention, duration and discontinuation strategies for opioid use disorder pharmacotherapy (RDD)".
    Shulman M; Weiss R; Rotrosen J; Novo P; Costello E; Nunes EV
    Addict Sci Clin Pract; 2021 Mar; 16(1):15. PubMed ID: 33676577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perceived social support in patients with chronic pain with and without opioid use disorder and role of medication for opioid use disorder.
    Benville JR; Compton P; Giordano NA; Cheatle MD
    Drug Alcohol Depend; 2021 Apr; 221():108619. PubMed ID: 33667781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of treatment duration on mortality among Veterans with opioid use disorder in the United States Veterans Health Administration.
    Ching JH; Owens DK; Trafton JA; Goldhaber-Fiebert JD; Salomon JA
    Addiction; 2021 Dec; 116(12):3494-3503. PubMed ID: 33999485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail.
    Velasquez M; Flannery M; Badolato R; Vittitow A; McDonald RD; Tofighi B; Garment AR; Giftos J; Lee JD
    Addict Sci Clin Pract; 2019 Oct; 14(1):37. PubMed ID: 31570100
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.